Recently, chronic administration of the dual GIP and GLP-1 receptor agonist in mice with diet-induced obesity potently decreased body weight and appetite, and these effects were significantly greater compared to that with GLP-1 receptor agonist treatment alone [9]. The gene discussed is GIP; the disease is obesity disorder.